Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: NMT Clear all

Conditions: Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyp of Colon
Interventions: Cold forcep polypectomy, Cold snare polypectomy; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, Ribociclib Succinate; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 254
States / cities: Jonesboro, Arkansas • Auburn, California • Berkeley, California + 210 more

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, thiotepa, allogeneic bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Congestive
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more

Conditions: Norovirus Infections
Interventions: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo; Drug
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota

Conditions: Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: epoetin alfa, thalidomide; Biological · Drug
Lead sponsor: Fallon Clinic; Industry
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 2
States / cities: Worcester, Massachusetts

Conditions: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
Interventions: ONTAK; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more

Conditions: Parkinson Disease
Interventions: Neurologic Music Therapy, Occupational Therapy, Music Supported Therapy; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Whitehouse Station, New Jersey

Conditions: Elevated Blood Pressure, Habitual Sleep Duration of Less Than or Equal to 7 Hours
Interventions: Sleep extension intervention, Health education; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Immune Reconstitution Inflammatory Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant
Interventions: Nasal Microbiota Transplant (NMT), Placebo; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Years to 60 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nelfinavir mesylate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 32
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more

Conditions: Malignant Neoplasm of Breast
Interventions: Novilase Laser ablation; Device
Lead sponsor: Novian Health Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Duarte, California • La Jolla, California • Rancho Mirage, California + 4 more

Conditions: PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten, Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Pomegranate-Extract Pill; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Burlington, Massachusetts • Minneapolis, Minnesota • San Antonio, Texas + 1 more

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions: Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more

Conditions: Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2
Interventions: Myozyme; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Gainesville, Florida • Durham, North Carolina • Cincinnati, Ohio

Conditions: Healthy, Athletic Performance
Interventions: Neuromuscular Training; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 14 Years to 18 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperkalemia
Interventions: Blood sample drawn from a vein, Blood sample drawn from a heel stick; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 6 Months
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: CAIV-T, Liquid; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 18 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Monroe, Wisconsin

Conditions: Corticobasal Syndrome, Upper Extremity Dysfunction
Interventions: Patterned Sensory Enhancement (PSE), Transcranial Direct Current Stimulation (tDCS); Behavioral · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 5 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 82
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more

Search by objective public record fields.

Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

NMT for Parkinson's Disease

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

Sleep Technology Intervention to Target Cardiometabolic Health

Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Agility and Performance Among High School Basketball Players Following a Coach-Led Neuromuscular Training Program

Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

Music and Brain Stimulation for Upper Extremity Performance in Patients With Corticobasal Syndrome

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease